Released · Last reviewed
Verify the pharmacy before you verify the price
Compounded semaglutide is only as safe as the pharmacy that makes it. The pharmacy is checkable in about ten minutes, and a program that won't name it has answered your question.
Before enrolling in a compounded semaglutide program, confirm five things: the dispensing pharmacy's legal name (disclosed before you pay), its current state license (verify on the state board of pharmacy lookup), whether it is a 503A pharmacy or 503B outsourcing facility, its FDA registration if 503B (on the FDA's registered facility list), and that a prescription is required after a genuine clinician evaluation. A program that won't name its pharmacy is disqualifying.
- Step one: The first and most revealing test: does the program tell you which pharmacy will fill your prescription, before you pay? A legitimate operation names .
- Step two: Every U.S.
- Step three: Compounded semaglutide comes from one of two facility types, and the difference matters.
- Step four: If the pharmacy is a 503B outsourcing facility, it must be registered with the FDA, and the FDA publishes the list of registered outsourcing facilitie.
- Step five: A legitimate program requires a prescription written after a licensed clinician actually evaluates you — a medical intake at minimum, sometimes a vide.
Step one: get the pharmacy's legal name
The first and most revealing test: does the program tell you which pharmacy will fill your prescription, before you pay? A legitimate operation names its pharmacy or pharmacies. “Our network of licensed pharmacies” with no names is a red flag — you cannot verify what you cannot identify, and the vagueness is usually deliberate.
Some programs disclose several possible pharmacies because fulfillment varies by state and availability; that's acceptable if each is named and verifiable. What's not acceptable is an unnamed “partner pharmacy” you only learn about, if ever, when the package arrives. The name is the key that unlocks every other check below.
| Check | How | Pass condition |
|---|---|---|
| Pharmacy named | Ask before paying | Legal name(s) disclosed |
| State license | State board lookup | Current, good standing |
| 503A vs 503B | Ask / pharmacy site | Known and appropriate |
| FDA registration (503B) | FDA outsourcing facility list | Listed |
| Prescription | Program intake | Required after real evaluation |
| Payment | Checkout | Card processing, receipts |
Step two: verify the state license
Every U.S. pharmacy is licensed by a state board of pharmacy, and every state board runs a free online license lookup. Enter the pharmacy's name and confirm the license is current and in good standing, licensed in a state, and — ideally — authorized to ship to yours. This takes minutes and catches the most basic failures.
A pharmacy that can't be found on any state board lookup is not a pharmacy you should let compound an injectable medication for you. Note the distinction that trips people up: state licensing is not FDA approval, and no pharmacy is “FDA-approved.” State boards license pharmacies; the FDA approves drugs and registers 503B facilities. A program claiming an “FDA-approved pharmacy” is either confused or misleading.
Step three: 503A or 503B?
Compounded semaglutide comes from one of two facility types, and the difference matters. A 503A pharmacy is a traditional compounding pharmacy that prepares patient-specific prescriptions; it is state-licensed but not subject to FDA current-good-manufacturing-practice (cGMP) requirements. A 503B outsourcing facility registers with the FDA, is inspected on a risk-based schedule, and must follow cGMP — more manufacturing assurance, more oversight.
Neither is “better” in every case, but you should know which you're getting. Post-shortage, 503A patient-specific compounding is the narrow legal lane for individualized semaglutide, while 503B copies of approved semaglutide are foreclosed. Our 503A-vs-503B guide covers what each status means for legality and quality.
Step four: check FDA registration for 503B
If the pharmacy is a 503B outsourcing facility, it must be registered with the FDA, and the FDA publishes the list of registered outsourcing facilities. Confirm the facility appears on it. Registration is not approval of any product — the FDA registers the facility, it does not approve compounded drugs — but an unregistered facility claiming 503B status is a serious warning sign.
For 503A pharmacies, there is no equivalent federal registry; the state license is your verification. In both cases, be alert to the language trap: “FDA-registered” (true for 503B facilities) is not “FDA-approved” (never true for compounded drugs). Marketing that blurs the two is testing whether you know the difference.
Step five: confirm a real prescription pathway
A legitimate program requires a prescription written after a licensed clinician actually evaluates you — a medical intake at minimum, sometimes a video visit depending on your state. If a seller offers semaglutide with no prescription, or a rubber-stamp “consultation” that approves everyone, that is the gray market, and the pharmacy questions above are usually moot because there isn't a real pharmacy behind it.
The prescription requirement is also your legal protection: possessing prescribed compounded medication is not the exposure that enforcement targets. “Research use only” products sold without prescriptions are a different and riskier category entirely — covered, with salt forms, in our gray-market guides.
The ten-minute checklist
Put together, the verification is fast: get the pharmacy's legal name before paying; find it on the state board of pharmacy license lookup and confirm current good standing; determine 503A or 503B; for 503B, confirm it's on the FDA registered-facility list; and confirm a prescription is required after a real clinician evaluation. Add the payment check — normal card processing, not crypto or gift cards — and you've screened out the large majority of unsafe sellers.
None of this requires expertise, just the willingness to spend ten minutes before spending your money and injecting the result. A program built for patients will pass every step and often volunteer the information; one built to move product will resist at the first step, which is the answer you needed.
Frequently asked questions
Is there such a thing as an 'FDA-approved pharmacy'?
No. State boards of pharmacy license pharmacies; the FDA approves drugs and registers 503B outsourcing facilities. No pharmacy is 'FDA-approved,' and a program using that phrase is either mistaken or misleading.
How do I check a pharmacy's license?
Use the relevant state board of pharmacy's online license lookup — every state has one, and they're free. Enter the pharmacy's legal name and confirm the license is current and in good standing.
What's the difference between 503A and 503B for me?
503A pharmacies prepare patient-specific prescriptions under state licensing; 503B outsourcing facilities register with the FDA and follow cGMP with FDA inspections. 503B carries more manufacturing oversight; 503A is the lane for individualized compounding.
Sources
- FDA — registered outsourcing facilities (503B) list
- NABP — pharmacy verification resources
- FDA — human drug compounding (503A/503B)
- Our 503A vs 503B guide
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $49 to $279 a month across the 22 programmes we priced on October 15, 2026, with a median of $99. The spread is $230 a month, or $2,760 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $87 and Eden at $99; lower stickers come with a sale, a prepaid year or a membership. Half the programmes sit below $99 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Two programmes printed a semaglutide microdose price on October 15, 2026 (Shed from $149, Noom Med $179); NexLife's microdose semaglutide has cost the same as its standard plan since November 8, 2026 ($109 a month month-to-month). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
How semaglutide is kept current
On October 15, 2026, compounded semaglutide ran $49 to $279 a month across the 22 programmes we priced. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
Standard-dose semaglutide spans $49 to $279 a month across the 22 programmes we priced on October 15, 2026, a spread of $230.
The molecule is chemically identical across every programme in the range. The $230 a month between the lowest and highest all-in semaglutide prices we read on October 15, 2026 ($49 and $279) is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why is microdosed semaglutide cheaper?
Because it is less medicine. On October 15, 2026, Shed listed a semaglutide microdose from $149 a month and Noom Med at $179 after a $79 start. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What does compounded semaglutide cost per month in October 2026?
As of October 15, 2026, the 22 compounded semaglutide programs we could price on their own pages charge between $49 and $279 a month at their lowest all-in rate, with a median of $99, counting any required membership and the cheapest plan term each program prints. The low end is made of sale and "as low as" prices: WellMedr's fall sale and NextMeds both start at $49. Standing month-to-month rates with no membership start at $87 (Mondae) and $99 (Eden). Compounded semaglutide is not FDA-approved.
What does compounded semaglutide normally cost?
$49 to $279 a month at the lowest all-in rate across the 22 programs we priced on October 15, 2026, with a median of $99. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.